Stock Ratings / Health Care / AVTR / earnings

TXG (65) BIO (66) BRKR (59) RVTY (68) ⌘ Pro Terminal →

Avantor Inc. (AVTR) Next Earnings Date & Expected ±6.2% Move

$16.05 -3.78% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.91

Avantor Inc. (AVTR) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $11.30B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AVTR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Avantor Inc. (NYSE: AVTR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $16.05 (-3.78% 1D, market cap $11.30B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, AVTR ranks #180 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AVTR compare to TXG and BIO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, TXG (10x Genomics Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC -5.7%, cap $10.63B) and BIO (Bio-Rad Laboratories Inc.) posts a C+ grade (66/100 RQD, P/E 13.5x, ROIC 0.5%, cap $10.28B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AVTR?

▼

Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.91 (-0.87%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 7.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE+0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVTR)Realized 20D OHLCV Swing Band: ±6.2%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY AVTR SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (31% of score)

20D Institutional Volume Accumulation (±6.2% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (19% of score)

FRED Regime × Technicals: 86% of 52W Range • RSI-14 at 57.4 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)

Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$15.55+6.9% Next Q

Q2 (-2Q)

Grade C-$16.62+3.1% Next Q

Q3 (-1Q)

Grade C$17.13-6.3% Next Q

Current

Grade C-$16.05+0.2% Hist 90D α

Trajectory: C- (51) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AVTR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, AVTR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 30.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.58) or 200D SMA ($11.24) invalidates the momentum regime and cuts Target Base ($16.12) toward Bear Floor ($12.57).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AVTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±6.2% Swing Band

±$1.00 Expected Swing

MODEL EARNINGS SETUP GAUGE

AVTR Quantitative Pre-Earnings Setup: 59/100

Trailing EPS: $-0.78 • YoY Revenue Growth: -3.4%

Model Bullish Setup (59/100)Model Risk Weight (41/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$6.55B	-$530.2M	$495.0M	32.7%
FY 2024	2024-12-31	$6.78B	$711.5M	$692.0M	33.6%
FY 2023	2023-12-31	$6.97B	$321.1M	$556.5M	32.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating AVTR & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on AVTR
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AVTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +100.88%🛡️ HOLDING TREND SUPPORT

2026-11-02O $16.69H $16.69L $16.05C $16.05VOL 11.22M

RES: $17.83SUP: $16.00SMA50: $15.58SMA200: $11.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVTR Butterfly Map → + Track AVTR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.9%/yr Implied 5Y Growth

vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AVTR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVTR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AVTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVTR)

Health Care Rank #180 of 1016 ⚔️ TXG vs AVTR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVTR vs. TXG, BIO, BRKR, RVTY)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Avantor Inc. (AVTR) ranks #180 by composite RQD confidence (59/100, grade C-) and #99 by equity capitalization ($11.30B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with AVTR at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AVTR ACTIVE Avantor Inc.	C-	59/100	—	32.7%	-2.1%	-3.78%	$11.30B	Benchmark Subject
TXG 10x Genomics Inc.	C	65/100	—	69.1%	-5.7%	-14.03%	$10.63B	/txg-vs-avtr →
BIO Bio-Rad Laboratories Inc.	C+	66/100	13.5x	51.9%	0.5%	-3.18%	$10.28B	/bio-vs-avtr →
BRKR Bruker Corporation	C-	59/100	—	45.9%	1.3%	-7.95%	$9.45B	/brkr-vs-avtr →
RVTY Revvity Inc.	C+	68/100	76.7x	—	3.1%	-5.30%	$18.50B	/rvty-vs-avtr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001722482

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avantor Inc. (AVTR) reported GAAP revenue of $6.55B (-3.4% vs. FY2024 revenue of $6.78B , and -6.0% cumulative change since FY2023) , GAAP net income of -$530.2M, operating cash flow of $623.8M, and free cash flow of $495.0M (-28.5% YoY). On the balance sheet, AVTR closed FY2025 with $11.79B in total assets against $3.92B in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.55B	-$530.2M	$623.8M	$495.0M	$11.79B	$3.92B
FY2024 (FY)	2024-12-31	$6.78B	$711.5M	$840.8M	$692.0M	$12.11B	$3.23B
FY2023 (FY)	2023-12-31	$6.97B	$321.1M	$870.0M	$556.5M	$8.36B	$1.96B

3. AVTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AVTR compare to TXG and BIO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AVTR?

Where is AVTR trading relative to its 50-day, 200-day, and 52-week technical levels?

AVTR last traded at $16.05 (-3.78% on volume of 9,733,870 shares), positioning the stock +3.02% above its 50-day simple moving average ($15.58) and +42.79% above its 200-day simple moving average ($11.24). Across its 52-week range of $7.26 to $17.45, AVTR sits at the 86.3% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.2% ($15.05 to $17.05).

AVTR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is AVTR's next earnings date?

Based on SEC filing cadence, Avantor Inc. (AVTR)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is AVTR stock expected to move on earnings?

Volatility modeling currently projects a ±6.2% event move for AVTR, spanning a range between $15.05 and $17.05.

Direct Sub-Reports: AVTR RQD Cockpit AVTR 12M Forecast AVTR Earnings & Move AVTR Dividends & DRIP AVTR Insiders & 13F AVTR Whale Options AVTR Profit Sankey AVTR News & Why

Sector Peer Dials

Bio-Rad Laboratories Inc.

Mettler-Toledo International Inc.

AVTR Core Snapshot

Market Cap $11.30B

Trailing / Fwd P/E — / 31.0x

Gross Profit Margin 32.7%

Return on Capital (ROIC) -2.1%

Free Cash Flow Yield 4.38%

12M Base Price Target $16.12

FREE TRADER TOOLS

Own AVTR Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With AVTR → 🏆 Trade AVTR in $100K Prop Arena →

AVTR Wire

Why It Moved →

Direct Company Event Yahoo Finance • 13h ago

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Direct Company Event Yahoo Finance • 16h ago

Avantor (AVTR) is Regaining Market Confidence

Direct Company Event Seeking Alpha • 19h ago

Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28

Direct Company Event GuruFocus • 22h ago

Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says

Direct Company Event Simply Wall St • 1d ago

Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AVTR — Avantor Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:15:56Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AVTR scores 59 out of 100, equating to a C- grade and the verdict "Roarable Hold — Cautious Neutral." The five pillars are:

Fundamental Cash Engine (10/20): Per the RQD rating, this pillar reflects ROIC of -2.1% and an FCF yield of 4.38%. Negative ROIC means the business is not currently earning returns above its capital base, a meaningful drag on this pillar. The positive FCF yield indicates the company still generates cash relative to its market value, which partially offsets the weak return profile.
Whale 13F Flow (18/20): This is the strongest pillar, described per the RQD rating as reflecting institutional accumulation and options positioning. For a prospective investor, this suggests larger holders have been building or maintaining positions, a potential support factor. The underlying 13F holder detail itself is not provided in the source data.
Insider Conviction (11/20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow at a moderate level. Mid-range insider signal suggests neither strong insider buying conviction nor significant selling pressure.
Macro Regime Fit (11/20): Per the RQD rating, beta is 1.01, meaning the stock has moved roughly in line with the market. Sector sensitivity is noted but not further quantified in the source data. Investors should expect returns to track broader market and sector conditions.
Forensic Balance Sheet (9/20): Per the RQD rating, Altman Z is 1.88, Piotroski F is 5/9, and Debt/Equity is 0.7. A Z-score in this range is commonly viewed as a financial-distress caution zone; the Piotroski score is moderate. This is the second-weakest pillar and a central risk consideration.

Investor implications: The rating points to a mixed picture. Upside drivers include institutional positioning and the positive FCF yield. Valuation tradeoffs are significant: the forward P/E of 31 is elevated relative to the negative trailing EPS of -0.78, and P/E (TTM) is not available in source data, so the valuation rests heavily on expectations of earnings recovery. The balance sheet and negative returns on capital are the principal headwinds. The verdict of "Cautious Neutral" reflects this balance rather than a directional call.

Business

Avantor Inc. is a NYSE-listed issuer classified under the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry, per the profile. The source data provides a market capitalization of $11.3B. Gross margin is 32.7% per the market data. Specifics on product lines, customer segments, and revenue mix are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$6552.2M	$-246.2M	$-530.2M	N/A	$495.0M	$365.4M	$3915.5M
FY 2024	$6783.6M	$1084.8M	$711.5M	N/A	$692.0M	$261.9M	$3234.7M
FY 2023	$6967.2M	$696.4M	$321.1M	N/A	$556.5M	N/A	$1956.4M

Per the SEC financials, revenue declined from $6967.2M (FY 2023) to $6552.2M (FY 2025), and FY 2025 moved to an operating loss of $-246.2M and net loss of $-530.2M after positive results in FY 2024. Operating margin is -3.8% and net margin is -8.1% per market data. ROIC is -2.1%. Per the RQD rating, the Altman Z-Score is 1.88 and the Piotroski F-Score is 5/9. Debt rose from $1956.4M (FY 2023) to $3915.5M (FY 2025), and Debt/Equity is 0.7 per the RQD rating.

Recent Catalysts & News Wire Analysis

Market wire (YELLOW): "Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?" — Yahoo Finance.
Catalyst (GREEN): "Avantor (AVTR) is Regaining Market Confidence" — Yahoo Finance.
Market wire (YELLOW): "Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28" — Seeking Alpha.
Catalyst (GREEN): "Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says" — GuruFocus.
Risk watch (RED): "Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall" — Simply Wall St.
Risk watch (RED): "Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution" — Yahoo Finance.

Per the news feed, catalyst items are mixed: two positive catalysts, two market-wire items, and two risk-watch items referencing the Q3 earnings reaction and the five-year decline. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments.

Open Questions

What drove the swing from FY 2024 net income of $711.5M to FY 2025 net loss of $-530.2M, and is it recurring or one-time?
What is the trailing P/E and EV/EBITDA, given both are unavailable in source data while forward P/E is 31?
How much of the $3915.5M debt load is near-term maturity, and what is the refinancing profile?
What are the drivers of the 13F accumulation signal, and which institutions are involved?
What is the FY 2025 EPS, which is reported as N/A?

AVTR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Avantor Inc. (AVTR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AVTR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 13h ago

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 16h ago

Avantor (AVTR) is Regaining Market Confidence

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 19h ago

Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28

Seeking Alpha report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 22h ago

Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says

GuruFocus report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall

Simply Wall St report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Here's Why You Should Add Avantor Stock to Your Portfolio for Now

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

3 Reasons to Sell AVTR and 1 Stock to Buy Instead

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AVTR Bull vs. Bear Conversation Board — What's Your Call at $16.05?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVTR 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $18.01 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AVTR (C- • RQD 59/100) a Buy at $16.68?

Welcome to the AVTR (Avantor Inc.) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.51 (-25.0%)

Spot @ $16.68

Pump the brakes on AVTR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AVTR, but look at what you are paying: current EV/EBITDA multiples with 32.7% gross margins. Unless Avantor Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $20.52 (+23.0%)

Spot @ $16.68

AVTR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AVTR, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $16.68 (52-wk range $7.26 - $17.45), any beat on forward guidance forces shorts and underweight funds to chase.